[go: up one dir, main page]

NO20015711L - Farmasöytiske preparater inneholdende anti-Fas-antistoff - Google Patents

Farmasöytiske preparater inneholdende anti-Fas-antistoff

Info

Publication number
NO20015711L
NO20015711L NO20015711A NO20015711A NO20015711L NO 20015711 L NO20015711 L NO 20015711L NO 20015711 A NO20015711 A NO 20015711A NO 20015711 A NO20015711 A NO 20015711A NO 20015711 L NO20015711 L NO 20015711L
Authority
NO
Norway
Prior art keywords
fas antibody
present
prophylaxis
antibody
pharmaceutical composition
Prior art date
Application number
NO20015711A
Other languages
English (en)
Other versions
NO20015711D0 (no
Inventor
Nobufusa Serizawa
Kimihisa Ichikawa
Hiroko Yoshida
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20015711D0 publication Critical patent/NO20015711D0/no
Publication of NO20015711L publication Critical patent/NO20015711L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Den foreliggende oppfinnelse tilveiebringer et nytt farmasøytisk preparat inneholdende et anti-Fas-antistoff som er anvendelig som et middel for profylakse og/eller behandling av en autoimmun sykdom eller revmatoid artritt. Mer spesielt tilveiebringer den foreliggende oppfinnelse et farmasøytisk preparat inneholdende et anti-humant Fas-antistoff med apoptoseinduserende virkning og en forbindelse med folatantagonistisk virkning eller en dihydrofolatreduk-taseinhiberende virkning som aktive ingredienser.I henhold til den foreliggende oppfinnelse er mengden av det anti-Fas-antistoffet som skal anvendes redusert i et middel for profylakse og/eller behandling av en autoimmun sykdom eller revmatoid artritt, og derved senkes muligheten for at pasienten blir tolerant for anti-Fas-antistoff som et resultat av fremstilling av antistoffer mot anti-Fas-antistoff i pasientens kropp eller lignende, og det tilveiebringes derfor et farmasøytisk preparat ifølge den foreliggende oppfinnelse som er anvendelig som et utmerket middel for profylakse og/eller behandling og som kan anvendes i et lengre tidsrom.
NO20015711A 1999-05-24 2001-11-23 Farmasöytiske preparater inneholdende anti-Fas-antistoff NO20015711L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14303399 1999-05-24
PCT/JP2000/003324 WO2000071160A1 (en) 1999-05-24 2000-05-24 MEDICINAL COMPOSITIONS CONTAINING ANTI-Fas ANTIBODY

Publications (2)

Publication Number Publication Date
NO20015711D0 NO20015711D0 (no) 2001-11-23
NO20015711L true NO20015711L (no) 2002-01-11

Family

ID=15329357

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015711A NO20015711L (no) 1999-05-24 2001-11-23 Farmasöytiske preparater inneholdende anti-Fas-antistoff

Country Status (19)

Country Link
US (1) US6746673B2 (no)
EP (1) EP1180369A4 (no)
KR (1) KR20020008197A (no)
CN (1) CN1191861C (no)
AU (1) AU761544C (no)
BR (1) BR0010909A (no)
CA (1) CA2373992A1 (no)
CZ (1) CZ20014181A3 (no)
HK (1) HK1042049A1 (no)
HU (1) HUP0201333A3 (no)
IL (1) IL146566A0 (no)
MX (1) MXPA01012206A (no)
NO (1) NO20015711L (no)
NZ (1) NZ515598A (no)
PL (1) PL352159A1 (no)
RU (1) RU2222347C2 (no)
TR (1) TR200103396T2 (no)
WO (1) WO2000071160A1 (no)
ZA (1) ZA200109575B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846637B1 (en) 1998-06-18 2005-01-25 Imed Ab Fas peptides and antibodies for modulating apoptosis
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
AU2003202093B2 (en) * 2001-07-02 2010-05-13 Aimsco Limited Treatment of MS with goat serum
US20100291102A1 (en) * 2001-07-02 2010-11-18 Ice Biologics Limited Therapeutic Agent
PE20030340A1 (es) * 2001-08-28 2003-04-05 Sankyo Co Metodo para el tratamiento o prevencion de desgaste oseo
US6989386B2 (en) * 2002-04-30 2006-01-24 Dana-Farber Cancer Institute Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
US20050032807A1 (en) * 2003-08-06 2005-02-10 Rosenwald Lindsay A. Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
CN101092417B (zh) * 2006-06-19 2011-04-27 上海金色医药科技发展有限公司 一种叶酸类似物及用于医疗的叶酸类似物的盐
AU2008310898B2 (en) 2007-10-08 2014-05-08 National Science and Technology Development Agency acting through National Center for Genetic Engineering and Biotechnology Antimalarial compounds with flexible side-chains
KR101784231B1 (ko) 2008-06-20 2017-11-08 노파르티스 아게 응집이 감소된 면역글로불린
KR101854724B1 (ko) 2008-06-20 2018-05-04 노파르티스 아게 단백질에서 거대분자 결합 및 응집 경향 영역을 확인하는 방법 및 그것의 사용
RU2492871C2 (ru) * 2008-08-01 2013-09-20 АКСИС, Инс. Терапевтическое или профилактическое средство для лечения остеоартрита
MX338775B (es) * 2009-06-04 2016-05-02 Novartis Ag Metodos para identificacion de sitios para conjugacion de igg.
EP2266984A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis
WO2011046309A2 (en) * 2009-10-12 2011-04-21 Korea Research Institute Of Bioscience And Biotechnology A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof
KR101138460B1 (ko) 2009-10-12 2012-04-26 한국생명공학연구원 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물
WO2014022817A2 (en) 2012-08-03 2014-02-06 Novartis Ag Methods to identify amino acid residues involved in macromolecular binding and uses therefor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK157451C (da) * 1979-06-14 1990-05-21 Wellcome Found Analogifremgangsmaade til fremstilling af 2,4-diamino-6-alkoxybenzyl-5-methylpyridooe2,3-daapyrimidiner eller farmaceutisk acceptable syreadditionssalte deraf
ZA861235B (en) * 1985-03-08 1986-10-29 Univ Princeton Pyrido(2,3-d)pyrimidine derivatives
DE3603577A1 (de) * 1986-02-06 1987-08-13 Joachim K Prof Dr Seydel Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
JPH02237935A (ja) 1989-03-10 1990-09-20 Bio Kagaku Kenkyusho:Kk エイズ処置剤
US5008391A (en) * 1989-07-07 1991-04-16 Eli Lilly And Company Enantioselective synthesis of antifolates
US4996207A (en) * 1990-01-18 1991-02-26 Nair Madhavan G Three new non-polyglutamatable deazaaminopterins
WO1991010448A1 (en) 1990-01-19 1991-07-25 German Cancer Research Center A cell surface antigen associated with cellular apoptosis
CA2071205C (en) 1990-01-19 2000-03-14 Peter H. Krammer Cell surface antigen associated with cellular apoptosis
CA2095518A1 (en) * 1990-11-14 1992-05-15 Jeffrey M. Blaney Specific inhibition of dihydrofolate reductase and compounds therefor
AU3276793A (en) * 1991-12-20 1993-07-28 Agouron Pharmaceuticals, Inc. Antifolate quinazolines
US5877176A (en) * 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
US5426110A (en) * 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
BR9607492A (pt) * 1995-01-16 1999-06-29 Commw Scient Ind Res Org Conjugados de ácidos graxos de composto terapêutico
US6221615B1 (en) * 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
US6004942A (en) * 1995-08-30 1999-12-21 The Regents Of The University Of California Methods for treating arthritis by administering an apoptosis regulator
WO1997034606A1 (en) * 1996-03-19 1997-09-25 Chugai Seiyaku Kabushiki Kaisha Uveitis remedy
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6001962A (en) * 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody
AU734758B2 (en) * 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies
US6098631A (en) * 1998-01-21 2000-08-08 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disease

Also Published As

Publication number Publication date
AU761544B2 (en) 2003-06-05
CA2373992A1 (en) 2000-11-30
AU761544C (en) 2004-02-12
HK1042049A1 (en) 2002-08-02
RU2222347C2 (ru) 2004-01-27
US6746673B2 (en) 2004-06-08
HUP0201333A2 (en) 2002-08-28
HUP0201333A3 (en) 2004-11-29
TR200103396T2 (tr) 2002-04-22
EP1180369A4 (en) 2002-07-24
MXPA01012206A (es) 2002-06-21
BR0010909A (pt) 2002-02-19
CZ20014181A3 (cs) 2002-03-13
PL352159A1 (en) 2003-07-28
ZA200109575B (en) 2003-04-30
KR20020008197A (ko) 2002-01-29
NO20015711D0 (no) 2001-11-23
EP1180369A1 (en) 2002-02-20
NZ515598A (en) 2004-05-28
CN1364090A (zh) 2002-08-14
US20020103212A1 (en) 2002-08-01
AU4948600A (en) 2000-12-12
CN1191861C (zh) 2005-03-09
IL146566A0 (en) 2002-07-25
WO2000071160A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
NO20015711L (no) Farmasöytiske preparater inneholdende anti-Fas-antistoff
Nordström et al. Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis
EP1206265A4 (en) SRC-KINASE INHIBITING COMPOUNDS
Le et al. Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs
YU45204A (sh) 3-BETA-D-RIBOFURANOZILTIAZOLO/4,5-d/ PIRIMIDINSKI NUKLEOZIDII NJIHOVA UPOTREBA
ATE455777T1 (de) Substituierte pyridoä3',2':4,5üthienoä3,2- düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü- pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
CA2173328A1 (en) HIV Protease Inhibitors
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
DK0730587T3 (da) 3-phenyl-2-isoxazoliner som anti-inflammatoriske midler
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
SG156524A1 (en) New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
EE05423B1 (et) IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon
RU2010142847A (ru) Противовоспалительные агенты
HUP0100520A1 (hu) Csontfelszívódást és sejtösszenövést gátló új szulfonamidszármazékok
TW200612969A (en) 3-β-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
SE0300445D0 (sv) New combination
ES2076894A1 (es) Derivados de 2-(4-(4-azolibutil)-1-piperacinil)-5-hidroxipirimidina, su preparacion y su aplicacion como medicamentos.
CA2364178A1 (en) N-benzenesulfonyl l-proline compounds as bradykinin antagonists
JP2006505582A5 (no)
GB0128109D0 (en) Therapeutic use
MY147899A (en) Piperidine derivatives useful as ccr5 antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application